What sector does United Therapeutics belong to?

United Therapeutics operates in the Health Care sector, specifically the Biotechnology industry, and is listed on the US markets.

What is the current share price of UTHR?

As of the latest available quote, UTHR traded at $497.11. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of UTHR?

United Therapeutics has a price-to-earnings (P/E) ratio of about 17.82. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of UTHR?

The market capitalisation of United Therapeutics is approximately $23.82B.

Is United Therapeutics profitable?

For its latest reported financial year, United Therapeutics recorded a net profit margin of about 41.94%.

Does UTHR pay a dividend?

United Therapeutics does not currently show a dividend yield in our data.

What is the return on equity (ROE) of UTHR?

United Therapeutics has a return on equity (ROE) of about 20.85%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of UTHR?

Over the past 52 weeks, UTHR has traded between a low of $396.12 and a high of $609.35.

United Therapeutics

UTHR US Health Care Biotechnology

S&P 400

$497.11

-1.34%

Delayed · cached 15 min

Fair value analysis

UTHR

United Therapeutics

$497.11

Close used for this calculation

$481.45Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

72/100

Profitability23/25

Returns13/25

Balance Sheet21/25

Efficiency15/25

Growth9/25

Strong

Quality radar

Consensus fair value

$481.45

Near FV

▼ -3.2% against the close used

Model range $295.86 – $592.93

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear$295.86Fair value$481.45Bull$592.93

FairClose

52-week traded range

52W low $397.9752W high $596.76

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading close to the consensus fair value

United Therapeutics closed at $497.11, 3.3% above the consensus fair value of $481.45 drawn from 8 valuation models.

Financial DNA score 72/100 — Strong. P/E of 17.8x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

$431.18

-13.3%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

$295.86

-40.5%

√(22.5 × EPS × BVPS)

EPS=27.86, BVPS=139.64 · outside Graham range (P/E 17.8, P/B 3.6) — asset-light, treat as a rough floor

P/E Fair Value

$557.20

+12.1%

EPS × 20x (sector P/E)

EPS=27.86, Sector P/E=20x

Peter Lynch (PEG)

$447.71

-9.9%

EPS × Growth% (PEG = 1 is fair)

EPS=27.86, g=16.1%

EV/EBITDA

$592.93

+19.3%

(EBITDA × 18x − Net Debt) ÷ Shares

EBITDA=1.58B

Book Value (P/B)

$518.40

+4.3%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=139.64, ROE=20.9%, g=6%, r=10%

Reverse DCF

$497.11

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 5.6% | Historical: 16.1%

Margin of Safety

$321.06

-35.4%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=428.08, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer